The stool bank OpenBiome has a new storefront in Massachusetts, WGBH News reports.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The assay has been available outside the US since November and runs on the Liaison MDX benchtop instrument.
The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month.
The test is the third in the firm's line of infectious disease assays, which also includes tests for meningococcus and Group B Strep.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
Nearly 8,000 patients participated in a screening study that used a PCR-based detection assay from Becton Dickinson, uncovering a 5 percent carrier rate.
A draft guidance issued by the US Food and Drug Administration regarding fecal microbiota transplants may affect how stool banks operate.
At the Personalized Medicine World Conference, researchers talked about how understanding the microbiome is leading to therapies aimed at keeping it healthy.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.